Yantai Dongcheng Pharmaceutical Group Co., Ltd. (SHE: 002675) has announced its acquisition of all rights to alfatide II across all diagnostic and therapeutic fields and indications.
Alfatide II, initially developed by Dr. Chen Xiaoyuan and previously licensed to Jiangsu Xinrui Pharmaceutical Co., Ltd. for further development, is currently in the Phase III clinical trial stage. Originally designed for the treatment of lung cancer, the drug represents a significant addition to Dongcheng Pharma’s portfolio as it advances toward potential commercialization.- Flcube.com
